Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment

Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social media post on January 25, 2025, on the platform X. The post detailed historical context, emphasizing the impact of motion sickness not only as a common disabling condition but also as a potential factor affecting national security.

The company remarked, “Motion sickness is not just a common everyday disabling condition but it can also impact national security. 80 years later Vanda has applied for the approval of a new drug, Tradipitant, to treat motion sickness.” This statement elucidates the motivation behind the research and development efforts of Vanda Pharmaceuticals.

Notably, the information disclosed as part of this regulatory filing under Item 7.01 shall not be considered as “filed” for obligations under the Securities Exchange Act of 1934, which shields it from specific liabilities under Section 18 of the Exchange Act. Furthermore, this data is not to be incorporated by reference in any filings under the Securities Act of 1933 or the Exchange Act, except through explicit reference in such filings.

As per the stipulations of the Securities Exchange Act of 1934, the report has been duly endorsed by Timothy Williams, Senior Vice President, General Counsel, and Secretary of Vanda Pharmaceuticals Inc. The signing took place on January 27, 2025, underscoring the company’s commitment to transparency and compliance with regulatory standards.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Vanda Pharmaceuticals’s 8K filing here.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.